Harm Reduction, By Mail: the Next Step in Promoting the Health of People Who Use Drugs

Benjamin T. Hayes · Jamie Favaro · Corey S. Davis · Gregg S. Gonsalves · Leo Beletsky · David Vlahov · Robert Heimer · Aaron D. Fox

Accepted: 22 February 2021 / Published online: 12 March 2021
© The New York Academy of Medicine 2021

**Keywords** Harm reduction · Injection drug use · Syringe services program · Naloxone · Mail-delivery · Online order

In 2020, accessing healthcare services through the Internet has become commonplace. Web sites offer discrete assessment and pharmaceutical management of conditions that may be associated with shame or social stigma, such as erectile dysfunction. Health insurance plans have simplified ordering and refilling medications through secure Web sites. Could this private and accessible approach to care delivery improve services for people who use drugs (PWUD)?

Providing harm reduction supplies, including sterile injection equipment and naloxone for overdose reversal, reduces morbidity and mortality for people who use drugs. Yet, despite the strong public health imperative, scaling these services to people in need has been slow and inadequate. Syringe service programs (SSPs) that distribute these supplies are unavailable in many areas of high need in the USA. Online access and mail-delivery may be a modern solution to problems that have limited the impact of harm reduction for decades.

The Scope of the Problem

Every year thousands are affected by preventable consequences of drug use. In 2018, there were 5600 new cases of hepatitis C virus (HCV) infection in the USA, almost all attributed to transmission from injection drug use [1]. Despite an overall trend in reduced HIV incidence among PWUD, outbreaks of HIV in drug using communities continue to occur. Most have occurred in locations where SSPs either do not operate or do so under constrained conditions. [2–5] Complications from
skin and soft tissue infections due to injection drug use, including infective endocarditis, have become increasingly common and more costly over the past 20 years [6–8]. Meanwhile, between 1999 and 2018, the number of Americans dying from opioid-involved overdoses increased 6-fold, reaching 46,802 people in 2018 [9, 10]. Overdose-related deaths have only accelerated since then, with more deaths recorded in the 12-month period ending May 2020 than in any other 12-month period on record [11]. There is mounting evidence that the COVID-19 pandemic has further aggravated already-worsening overdose trends, including by exacerbating access to harm reduction and treatment resources [12].

Indeed, providing harm reduction supplies has long been demonstrated to prevent morbidity and mortality, while improving health outcomes among PWUD. Adequate access to sterile syringes reduces transmission of HIV and HCV [13, 14]. Likewise, naloxone, a full opioid antagonist, quickly and effectively reverses opioid overdose in most cases [15, 16]. Leading health agencies, including the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the Office of the US Surgeon General, recognize access to sterile syringes and naloxone as evidence-based practices for public health [17–22].

Yet, program coverage remains dismal, so most PWUD in the USA have no or inadequate access to these harm reduction services. One review estimated that in the USA, people who inject drugs have access to only 39 syringes per year, yet the WHO has recommended that reducing blood-born pathogen transmission risk requires closer to 200 per year [23]. The CDC has identified 220 rural counties in 26 states that are vulnerable to outbreaks of HCV and HIV due to injection drug use [24], yet only 7% of those counties have SSPs [25].

While new laws have been associated with increased access to naloxone from pharmacies and community organizations, naloxone is often unavailable when and where it is needed [26, 27]. More than 40% of fatal opioid overdoses are witnessed and therefore preventable if naloxone were readily available [28]. Why does this great need for evidence-based harm reduction services remain unmet?

---

A Historical Perspective

The stepwise evolution of harm reduction services in the US provides context to our current deficits in meeting the health needs of PWUD. During the 1980s HIV crisis, activists began providing relatively small amounts of sterile injection equipment. These early SSPs, illegal at the time, served as vital sources of supplies for PWUD communities [29]. Early programs were centered in urban areas, where HIV transmission through injection drug use was most common, and where there was sufficient political support to sustain their existence [29–31]. Despite high levels of need throughout the country, expansion was limited locally by fierce political and public resistance rooted in stigma toward PWUD and nationally by a ban on federal funding for SSPs that was dating from 1986 [32]. Within the confines of limited funding and political opposition, SSPs created innovative solutions including distributing supplies without requiring one-for-one exchange and encouraging secondary exchange through peer delivery [29]. Even after the ban was eased in 2016, allowing federal funds to be used to support SSPs, federal money appropriated to the departments of Health, Labor, and Education still may not be used to purchase needles or syringes [33]. Local opposition based in stigma against PWUD continues to impede the opening of new drop-in SSPs [33, 34]. Although SSPs positively impact health outcomes, their reach continues to be limited.

The spread of the opioid crisis to rural and suburban areas that intensified in the 2000s profoundly illuminates the missed opportunities to prevent harm. Fostered by under-regulated distribution of pharmaceuticals and belated attempts at opioid supply reduction, PWUD with opioid use disorder in regions that have had historically the lowest numbers of SSP in the country, turned to intravenous heroin and fentanyl use. With Scott County, Indiana as a notable example, non-urban areas were hit with HIV and HCV outbreaks and carried a disproportionate burden of the surging HCV infection rates [2, 35]. However, the risks imposed by poor geographic access to SSPs are not limited to rural areas. An HIV outbreak in an urban area of Massachusetts with insufficient syringe access demonstrates the ubiquity of the problem [36]. Some states have since modified restrictive laws that prevented SSP operations, and the number of SSPs nearly doubled from 2015 to 2017 [32]. However, laws and regulatory bodies place severe, non-
evidence-based limitations on starting and operating SSPs, limiting their reach. In fact, fewer than 300 SSPs were known to exist nationwide as of 2018 and most PWUD remain without local access to harm reduction supplies [37]. Even for programs that are able to function above ground, police interference with clients and staff often impede optimal operation [38–40]. Innovative service delivery models that are rapidly scalable and widely available are urgently required to meet this need.

Rationale for Online Accessed and Mail-Delivered Services

We believe that mail-delivery of harm reduction supplies, including sterile injection equipment and naloxone for overdose prevention, can help bring these commodities to PWUD by streamlining transactions and eliminating the need for a local agency to mediate. Mail can reach anywhere in the country, removing geographic barriers. Through the ubiquity of smartphones and wireless Internet, users can order supplies through confidential Web sites and secure messaging applications, providing ease of access, broad availability, and rapid scalability. Online ordering and mail delivery are also discreet, affording participants confidence in their privacy and security. Moreover, mail-delivery circumvents concerns from community members that drop-in centers would exacerbate crime and the “not-in-my-backyard” challenges that have thwarted many SSPs [41].

NEXT Harm Reduction provides proof of concept for this model. Founded in 2017, NEXT was the first formal mail-delivered harm reduction program in the USA, providing free sterile injection equipment, naloxone, and harm reduction education to PWUD. They also provide supplies for proper disposal of syringes. Harm reduction advocates have used the mail to distribute harm reduction supplies informally for years [42]. However, NEXT formalized this practice by designing a secure and confidential online platform for people to request supplies, communicate with staff, and access harm reduction information. Our initial analysis of transaction data from NEXT suggests that their services are in high demand. For example, in just 2.5 years, NEXT has distributed over 600,000 sterile syringes to over 800 unique enrollees. Importantly, these services are being utilized by people with high needs, reaching high proportions of women, people living with HCV, and people who report no other access to sterile syringes. These data provide a compelling case that making mail-delivered services more widely available could have an important impact on the health of PWUD.

NEXT does not supplant existing drop-in harm reduction services, but rather augments already existing programs. NEXT is authorized to distribute harm reduction supplies in New York State and has established partnerships with local agencies in California, Michigan, Louisiana, and Nevada. When a state resident cannot access an in-person SSP, staff members from the SSP can direct them to NEXT, which provides a way to confidentially request supplies and has the logistics to mail them. NEXT also refers people who would benefit from in-person services to local SSPs when available. SSPs continue to be the hub of local harm reduction efforts, while NEXT’s unique online platform and mail-delivery services allows them to reach more people in need. Forty-two states have at least one harm reduction agency [43], thus expanding partnerships between NEXT, or similar organizations, and these local agencies is a feasible and locally sensitive means of addressing the health services shortages. In the states without local harm reduction agencies, mail-delivered harm reduction could act as the provisional source of safe injection equipment and naloxone. The NEXT model shows great promise, but expanded funding and simple policy changes would make adequate access a reality.

Legal Landscape of Mail-Order Services

Federal and state laws can complicate the mailing of both injection supplies and naloxone. Most states continue to criminalize possession of syringes when the intended use is to inject illicit drugs or misused medications [44]. While many have modified these laws to permit SSPs to dispense injection supplies, the rules governing such programs continue to be restrictive. For example, seven states that allow SSPs continue to lack explicit legal protections for syringe possession [45]. In other states, laws only allow possession of syringes at the physical location of an SSP. [37]

Mailing syringes often requires authorization by a state entity and affiliation with an authorized SSP. [46] Further, some states have regulations that make it difficult for syringes to be mailed, such as requiring onsite HIV and HCV testing, or limiting
distribution to officially designated geographic areas [45]. In contrast, unrestricted syringe policies are associated with increased acquisition of sterile syringe supplies [47]. For mail-delivery to be broadly expanded, participants must have confidence that they will not face prosecution or penalties for using these services.

Many states have erected no clear barrier to authorized SSPs distributing syringes by mail, and some states have even expanded what is permissible in light of the COVID-19 pandemic. For example, in March 2020 Maine’s Governor issued an Executive Order permitting SSPs to distribute injection supplies via mail [48]. However, there are still very few programs using these methods; as of April 2020, only 6% of 173 surveyed SSPs reported mailing injection supplies [49]. Clarifying and modifying these laws could address this crisis.

In many states, broad naloxone access laws permit authorized individuals to distribute naloxone to people at risk of overdose and people who may come in contact with them [50]. Federal law generally defers to state law regarding who can use mail to distribute medications that are not controlled substances, like naloxone [51]. Policy changes at the state level would remove major legal obstacles to mail-delivery of both sterile syringes and naloxone.

Overcoming Barriers

We recommend additional public and private funding be allocated to support mail-delivered harm reduction supplies. Funding should support the expansion of NEXT and build the capacity of other organizations interested in replicating similar programs. Funding should also be increased for local harm reduction programs to include mail-delivery services, such as through affiliates like NEXT. To overcome legal barriers, legislators should remove laws and policies that restrict rapid expansion of mail-delivery harm reduction, such as changing paraphernalia laws to completely exempt syringes, naloxone and other harm reduction supplies [37]. Failing that, they should clarify that any person or entity authorized to distribute harm reduction supplies can do so via mail and remove other barriers, such as geographic limitations on the areas an SSP can serve.

Conclusion

Online ordering and mail-delivery is widely used for a range of health services and products. Leveraging these tools for harm reduction services would rapidly expand the reach of sterile injection equipment and naloxone to underserved areas. Broadly supporting these efforts through policy change and targeted funding can maximize the public health impact and lives of PWUD.

Acknowledgements This research was supported by the National Institute Allergy and Infectious Diseases CFAR Grant P30AI124414. Dr. Fox is supported by the National Institutes of Health under Grant R01DA044878.

References

1. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance – United States. 2018. Available at: https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm. Accessed 15 Dec 2020.
2. Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375(3):229–39.
3. Cranston K, Alpren C, John B, et al. Notes from the field: HIV diagnoses among persons who inject drugs - Northeastern Massachusetts, 2015-2018. MMWR Morb Mortal Wkly Rep. 2019;68(10):253–4.
4. Quilter LAS, Aignew-Brune C, Broussard D, et al. Establishing best practices in a response to an HIV cluster: an example from a surge response in West Virginia. Sex Transm Dis. 2021;48(3):e35–40.
5. Tookes H, Bartholomew TS, Geary S, Matthias J, Poschman K, Blackmore C, et al. Rapid identification and investigation of an HIV risk network among people who inject drugs - Miami, FL, 2018. AIDS Behav. 2020;24(1):246–56.
6. Ciccarone D, Unick GJ, Cohen JK, Mars SG, Rosenblum D. Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions. Drug Alcohol Depend. 2016;163:126–33.
7. Wurcel AG, Anderson JE, Chai KK, et al. Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infect Dis. 2016;3(3):ofw157.
8. Capizzi J, Leahy J, Wheelock H, Garcia J, Strnad L, Sikka M, et al. Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018. PloS One. 2020;15(11):e0242165.
9. Wilson LE, Thomas DL, Astemborski J, Freedman TL, Vlahov D. Prospective study of infective endocarditis among injection drug users. J Infect Dis. 2002;185(12):1761–6.
10. Centers for Disease Control and Prevention. The drug overdose epidemic: Behind the numbers. Available at: https://www.cdc.gov/drugoverdose/data/index.html. Accessed 10 Dec 2020.
11. Centers for Disease Control and Prevention. Overdose deaths accelerating during COVID-19. Available at: https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html. Accessed 15 Jan 2021.

12. Friedman J, Beletsky L, Schriner DL. Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic. JAMA Psychiatry. 2020;

13. National Research Council (US) and Institute of Medicine (US) Panel on Needle Exchange and Bleach Distribution Programs. Preventing HIV Transmission: The Role of Sterile Needles and Bleach. Normand J, Vlahov D, Moses LE, editors. Washington (DC): National Academies Press (US); 1995. PMID: 25121230.

14. Wodak A, McLeod L. The role of harm reduction in controlling HIV among injecting drug users. Aids. 2008;22(Suppl 2):S81–92.

15. Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med. 1994;12(6):650–60.

16. McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids—Conception and maturation. Drug Alcohol Depend. 2017;178:176–87.

17. Centers for Disease Control and Prevention. Summary of information on the safety and effectiveness of syringe services programs (SSPs). Available at: https://www.cdc.gov/ssp/syringe-services-programs-summary.html. Accessed 10 Dec 2020.

18. Centers for Disease Control and Prevention. Evidence-based strategies for preventing opioid overdose: what’s working in the United States: an introduction for public health, law enforcement, local organizations, and others striving to serve their community. Available at: http://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf. Accessed 10 Dec 2020.

19. Satcher D. Evidence-based findings on the efficacy of syringe exchange programs: an analysis of the scientific research completed since April 1998. Washington, DC: United States Department of Health and Human Services. p. 2000.

20. Adams J. U.S. Surgeon General’s advisory on naloxone and opioid overdose. Available at: https://www.hhs.gov/surgeongeneral/priorities/opioids-and-addiction/naloxone-advisory/index.html. Accessed 10 Dec 2020.

21. World Health Organization. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. 2004; 9241591641. https://www.who.int/hiv/pub/prev_care/effectivenesssterileneedle.pdf. Accessed 10 Dec 2020.

22. World Health Organization. Community management of opioid overdose. Geneva, Switzerland: 2014.

23. Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–20.

24. Van Handel MM, Rose CE, Hallisey EJ, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323–31.

25. amfAR. Syringe services programs and the opioid epidemic. Available at: https://www.amfar.org/ssp-opioid-epidemic/. Accessed 10 Dec 2020.

26. Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018;189:37–41.

27. Lambdin BH, Davis CS, Wheeler E, Tueller S, Kral AH. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States. Drug Alcohol Depend. 2018;188:370–6.

28. Mattson CL, O’Donnell J, Kariisa M, Seth P, Scholl L, Gladden RM. Opportunities to prevent overdose deaths involving prescription and illicit opioids, 11 States, July 2016–June 2017. MMWR Morb Mortal Wkly Rep. 2018;67(34):945–51.

29. Des Jarlais DC. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J. 2017;14(1):51.

30. O’Keefe E. Altering public policy on needle exchange: the Connecticut experience. AIDS Publ Policy J. 1991;6(4):159–64.

31. Dempsey MA. A Shot in the Arm: Legal & Social Obstacles to United States Needle Exchange Programs. BCThird World LJ. 1997;17:31.

32. Des Jarlais DC, Feelemeyer J, LaKosky P, Szmanyadowksi K, Arasteh K. Expansion of syringe service programs in the United States, 2015-2018. Am J Public Health. Apr 2020;110(4):517–9.

33. Centers for Disease Control and Prevention. Syringe Services Programs, Determination of Need. Available at: https://www.cdc.gov/ssp/determination-of-need-for-ssp.html. Accessed 20 Dec 2020.

34. Jones CM. Syringe services programs: an examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S. Int J Drug Policy. Aug 2019;70:22–32.

35. Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–8.

36. Alpren C, Dawson EL, John B, Cranston K, Panneer N, Fukuda HD, et al. Opioid Use Fueling HIV Transmission in an urban setting: an outbreak of HIV infection among people who inject drugs-Massachusetts, 2015-2018. Am J Public Health. 2020;110(1):37–44.

37. Davis CS, Carr DH, Samuels EA. Paraphernalia laws, criminalizing possession and distribution of items used to consume illicit drugs, and injection-related harm. Am J Public Health. 2019;109(11):1564–7.

38. Davis CS, Burris S, Kraut-Becher J, Lynch KG, Metzger D. Effects of an intensive street-level police intervention on syringe exchange program use in Philadelphia, PA. Am J Public Health. 2005;95(2):233–6.

39. Beletsky L, Heller D, Jenness SM, Neaigus A, Gelpi-Acosta C, Hagan H. Syringe access, syringe sharing, and police encounters among people who inject drugs in New York
City: a community-level perspective. *Int J Drug Policy*. 2014;25(1):105–11.

40. Beletsky L, Grau LE, White E, Bowman S, Heimer R. The roles of law, client race and program visibility in shaping police interference with the operation of US syringe exchange programs. *Addiction*. Feb 2011;106(2):357–65.

41. Beletsky L, Judd Lieberman A, Davis CS, Wahbi RN. RE: Proposed Ordinance NO. NS-XXX amending the Santa Ana Municipal Code (Health and Sanitation) prohibiting syringe exchange programs in the City of Santa Ana. Northeastern University School of Law Research Paper. 2020. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3694563. Accessed 13 Jan 2021.

42. Szalavitz M. How one group is expanding access to overdose-reversal drugs through the mail. *Vice Magazine*. https://www.vice.com/en/article/gyamdy/naloxone-narcan-by-mail. Accessed 14 Jan 2021.

43. North American Syringe Exchange Network (NASEN). SEP locations. Available at: https://www.nasen.org/map/. Accessed 10 Dec 2020, 2020.

44. Burris S. Syringe distribution laws. 2017. http://lawatlas.org/datasets/syringe-policies-laws-regulating-non-retail-distribution-of-drug-parapherna. Accessed 15 Jan 2021.

45. Fernández-Viña MH, Prood NE, Herpolsheimer A, Waimberg J, Burris S. State Laws Governing Syringe Services Programs and Participant Syringe Possession, 2014-2019. *Public Health Rep*. 2020;135(1_suppl):128s–37s.

46. The Policy Surveillance Program. Syringe service program laws. 2019. http://lawatlas.org/datasets/syringe-services-programs-laws. Accessed 15 Jan 2021.

47. Janulis P, Montgomery BW, Anthony JC. Estimated effect of US state syringe sale policy on source of last-used injection equipment. *Int J Drug Policy*. 2020;76:102625.

48. Executive order 27: An order regarding state certified hypodermic apparatus exchange programs (2020).

49. Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC. The Impact of COVID-19 on Syringe Services Programs in the United States. *AIDS Behav*. 2020;24(9):2466–8.

50. Davis C, Carr D. State legal innovations to encourage naloxone dispensing. *J Am Pharm Assoc* (2003). 2017;57(2s):S180–s184.

51. Davis C. Determining whether federal law prohibits the mailing of naloxone. *The Network for Public Health Law*. Available at: https://www.networkforphl.org/news-insights/determining-whether-federal-law-prohibits-the-mailing-of-naloxone/. Accessed 15 Jan 2021.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.